1-4 of 4
David McKenzie, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 3629.
https://doi.org/10.1182/blood.V112.11.3629.3629
Published: 2008
Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 1653.
https://doi.org/10.1182/blood.V112.11.1653.1653
Published: 2008
Journal Articles

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, Linda Zimmerman, BSN, David McKenzie, MS, C. L. Beach, PharmD, Lewis B. Silverman, MD
Journal: Blood
Blood (2008) 112 (11): 3636.
https://doi.org/10.1182/blood.V112.11.3636.3636
Published: 2008
Journal Articles

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 227.
https://doi.org/10.1182/blood.V112.11.227.227
Published: 2008